Director Zeiher purchases 5.0K TRDA shares at $5.86; stock down -61.6% from 52-week high amid -87.9% revenue decline
Bernhardt G Zeiher, as a director, purchased 5,000 shares of Entrada Therapeutics at $5.86 on 2026-05-20, establishing an initial position in the company. The purchase comes as TRDA faces significant operational headwinds: quarterly revenue has collapsed to $875,000.00 against a net loss of $-39,717,000.00, with annual revenue declining -87.9% year-over-year. The stock has suffered steep declines, trading at $6.31 currently—down -61.6% from its 52-week high of $16.45 and -51.7% over the past 30 days. Zeiher's cross-ticker track record shows 1 prior buy with an average 90-day return of +37.8%, though this isolated prior transaction provides limited predictive value for performance at this specific ticker. The purchase reflects director participation in a distressed biotech name with severe revenue deterioration and consistent unprofitability.